Drug Trial Radar · NCT03796962
A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy
Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
325
Actual
Start
Jan 30, 2019
Primary completion
Sep 2, 2021
Study completion Oct 2030
Sponsor
- Lead sponsor
- Xenon Pharmaceuticals Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Novotech Health Holdings Pte. Ltd.
- First posted
- Jan 8, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The XEN1101 Phase 2 clinical trial is a randomized, double-blind, placebo-controlled study that will evaluate the clinical efficacy, safety and tolerability of increasing doses of XEN1101 administered as adjunctive treatment in adult patients diagnosed with focal epilepsy, followed by an optional open-label extension (OLE).
Conditions
- Focal Epilepsy
Interventions
XEN1101Drug
Oral dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Median Percent Change in Focal Seizure FrequencyTime frame: From baseline (8 weeks prior to Day 0) through to the final dose (up to Day 56)
Locations
95 sites in 9 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Strada Patient Care Center
Mobile, Alabama
Xenoscience, Inc.
Phoenix, Arizona
Clinical Trials, Inc.
Little Rock, Arkansas
Altman Clinical Translational Research Institute (ACTRI)
La Jolla, California
California Pacific Medical Center (CPMC) - Sutter Pacific Epilepsy Program
San Francisco, California
University of Colorado Hospital Anschutz Outpatient Pavilion
Aurora, Colorado
University of Florida Jacksonville
Jacksonville, Florida
Mayo Clinic Florida
Jacksonville, Florida
Visionary Investigators Network
Miami, Florida
Don Clinical Research Center
Miami, Florida
The Neurology Research Group, LLC.
Miami, Florida
Research Institute of Orlando, LLC
Orlando, Florida
Medsol Clinical Research Center
Port Charlotte, Florida
Tallahassee Neurological Clinic
Tallahassee, Florida
University of South Florida
Tampa, Florida
Georgia Neurology and Sleep Medicine Associate
Suwanee, Georgia
Hawaii Pacific Neuroscience
Honolulu, Hawaii
Consultants in Epilepsy and Neurology, PLLC
Boise, Idaho
Northwestern Medical Group, Department of Neurology
Chicago, Illinois
University of Kansas Medical Center
Kansas City, Kansas
Bluegrass Epilepsy Research
Lexington, Kentucky
Maine Medical Partners Neurology
Scarborough, Maine
Mid-Atlantic Epilepsy and Sleep Center
Bethesda, Maryland
Boston Neuro Research Center
Russells Mills, Massachusetts
Minneapolis Clinic of Neurology, Ltd.
Golden Valley, Minnesota
Minnesota Epilepsy Group, P. A.
Saint Paul, Minnesota
Northeast Regional Epilepsy Group
Hackensack, New Jersey
Institute of Neurology and Neurosurgery at Saint Barnabas
Livingston, New Jersey
Northeast Regional Epilepsy Group
Morristown, New Jersey
Dent Neurosciences Research Center
Amherst, New York
NYU Langone Medical Center/NYU School of Medicine
New York, New York
Northwell Health - Lenox Hill
New York, New York
SUNY Upstate Medical University Institute for Human Performance
Syracuse, New York
Five Towns Neuroscience Research
Woodmere, New York
Asheville Neurology Specialists, PA
Asheville, North Carolina
UC Gardner Neuroscience Institute
Cincinnati, Ohio
Miami Valley Hospital
Dayton, Ohio
University of Toledo Medical Center
Toledo, Ohio
Providence Neurological Specialties East
Portland, Oregon
Showing 40 of 95 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.